MedTrace Logo

The Effectiveness of Almotriptan Malate (AXERT®) 12.5 Milligrams When Taken at the Onset of Migraine Pain

NCT00212823 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1450

Last updated 2011-05-19

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effectiveness and safety of AXERT when treating a migraine at the onset of headache pain, as compared to treating a migraine only after the headache pain has reached at least moderate intensity..

Conditions

Interventions

DRUG

almotriptan malate

Sponsors & Collaborators

  • Ortho-McNeil Neurologics, Inc.

    lead INDUSTRY

Principal Investigators

  • Ortho McNeil Neurologics, Inc. Clinical Trial · Ortho-McNeil Neurologics, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-06-30
Completion
2005-02-28

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00212823 on ClinicalTrials.gov